Vaccines for Cancer Immunotherapy An Evidence-Based Review on Current Status and Future Perspectives
Coordonnateurs : Rezaei Nima, Keshavarz-Fathi Mahsa
Therapeutic cancer vaccines represent a type of active cancer immunotherapy. Clinicians, scientists, and researchers working on cancer treatment require evidence-based and up-to-date resources relating to therapeutic cancer vaccines. Vaccines for Cancer Immunotherapy provides a reference for cancer treatment for clinicians and presents a well-organized resource for determining high-potential research areas. The book considers that this promising modality can be made more feasible as a treatment for cancer. Chapters cover cancer immunology, general approaches to cancer immunotherapy, vaccines, tumor antigens, the strategy of allogeneic and autologous cancer vaccines, personalized vaccines, whole-tumor antigen vaccines, protein and peptide vaccines, dendritic cell vaccines, genetic vaccines, candidate cancers for vaccination, obstacles to developing therapeutic cancer vaccines, combination therapy, future perspectives and concluding remarks on therapeutic cancer vaccines.
1. Cancer immunology 2. Immunotherapeutic Approaches in Cancer 3. Vaccines, Adjuvants, and Delivery Systems 4. Tumor Antigens 5. Strategy of Allogeneic and Autologous Cancer Vaccines 6. Personalized Cancer Vaccine 7. Whole Tumor Cell Vaccine for Cancer 8. Peptide and Protein Vaccines for Cancer 9. Immune Cell Vaccine for Cancer 10. Genetic Vaccine for Cancer 11. Candidate Cancers for Vaccination 12. Obstacles in the Development of Therapeutic Cancer Vaccines 13. Combination Therapy: Cancer Vaccines and Other Therapeutics 14. Concluding Remarks and Future Perspectives on Therapeutic Cancer Vaccines
Interdisciplinary: clinicians, scientists and researchers working on applying different modalities for cancer treatment, including biological therapies; immunologists, oncologists, biotechnologists, and other specialists dealing with cancer research and therapy
Mahsa Keshavarz-Fathi is a medical researcher and MD candidate at Tehran University of Medical Sciences (TUMS). She is also the managing director of the Cancer Immunology Project (CIP) and Breast Cancer Association (BrCA) undertaking and managing different research projects in the field of cancer treatment, cancer immunology and immunotherapy.
- Introduces the feasible immunotherapeutic vaccines for patients with different types of cancer
- Presents the status of past and current vaccines for cancer treatment
- Considers advantages and disadvantages of different therapeutic cancer vaccines
- Looks at the combination of vaccines and other modalities, including immunotherapeutic and conventional methods
- Analyzes obstacles to development of therapeutic cancer vaccines
- Gives a view on future perspectives in the application of therapeutic cancer vaccines
Date de parution : 10-2018
Ouvrage de 198 p.
19x23.3 cm
Thèmes de Vaccines for Cancer Immunotherapy :
Mots-clés :
4-1BB; Active immunotherapy; Adaptive immunity; Adjuvant; Adverse effect; Allogeneic vaccine; Approved drugs; Autologous vaccine; Belagenpumatucel-L; Cancer immunology; Cancer vaccine; Cancer; CD40Chemotherapy; CIMAvax-EGF; Clinical trial; CLRs ligands; Combination therapy; CTLA-4Cyclophosphamide; Cytokines; DCs; Delivery system; Dendritic cells; Designing clinical trials; DNA vaccine; Docetaxel; E75gp100GVAX; Efficacy; EGF-P64K; Elimination; Epitope spreading; Equilibrium; Escape; Gene delivery; Genetic vaccine; Genomics; Glycolipid antigen; Glycoprotein antigen; gp100L-BLP25MAGE-A3Optimization; GVAX; IFA; Immune checkpoint blockade; Immune response; Immunoediting; Immunopharmacogenomics; Immunosuppression; Immunosuppressive factors; Immunotherapy; Individualized cancer vaccine; Innate immunity; Irradiated gene-modified tumor cell; LAG-3OX40PD-1Radiation therapy; L-BLP25MAGE-A3 vaccine; Lymphocytes; Macrophages; MDSCs; Mono-epitope antigen; Neoantigen; Neoantigens; NeuVax; NK cells; Oncophage; Optimization; Overall survival; Passive immunotherapy; Peptide vaccine; Personalized immunotherapy; Personalized medicine; Poly-epitope antigen; Predictive biomarkers; Preventive vaccine; Prior treatment; Prophylactic vaccine; PROSTVAC-VF (TRICOM)Provenge; Protein vaccine; RNA vaccine; Route of administration; Sipuleucel-T; Small molecule inhibitors; STING ligands; Synthetic long-peptide vaccine; Therapeutic cancer vaccine; Therapeutic vaccine; Tim-3TLRs ligand; Tregs; Tumor antigen; Tumor burden; Tumor cell lysates; Tumor regression; Tumor vaccines; Tumor-associated antigen; Tumor-derived exosomes; Tumor-specific antigen; Vaccine
